Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bankinter, Bongrain, Nyrstar, Vopak: European Equity Preview

The following companies’ shares may have unusual moves in European trading. Stock symbols are in parentheses.

The Stoxx Europe 600 Index fell 1.2 percent to 277.88. The Stoxx 50 Index declined 1 percent to 2,611.80. The Euro Stoxx 50 Index, a benchmark for nations using the euro, dropped 0.9 percent to 2,909.73.

Bankinter SA (BKT SM): The Spanish lender needs 333 million euros of new capital, the Bank of Spain said. The bank has said it will issue 406 million euros in bonds that must be converted into shares. The stock lost 1.6 percent to 4.58 euros.

Bongrain SA (BH FP): The dairy-product manufacturer said net income rose 83 percent in 2010 to 81.4 million euros last year. The company will pay a dividend of 1.6 euros per share. The shares of Bongrain rose 1.2 percent to 62.83 euros.

Nyrstar NV (NYR BB): Existing investors in the world’s largest producer of refined zinc have until 4 p.m. in Brussels to buy seven new shares at 7 euros apiece for every 10 they hold. Nyrstar lost 2.5 percent to 9.91 euros. The subscription rights (NYR3 BB) fell 8.6 percent to 2.01 euros.

Royal Vopak NV (VPK NA): The world’s largest chemical and oil storage company may report full-year net income rose to 276.8 million euros, according to the average estimate of nine analysts surveyed by Bloomberg. Vopak retreated 0.9 percent to 34.78 euros.

Telegraaf Media Groep NV (TELEG NA): The Dutch newspaper publisher may report full-year profit excluding some items of 52.9 million euros ($73.1 million), according to the average of four analyst estimates compiled by Bloomberg. Telegraaf rose 0.1 percent to 14.32 euros.

ThromboGenics NV (THR BB): The Belgian developer of the microplasmin retinal-disorder medicine said it plans to seek U.S. and European regulatory approval for the experimental drug in the second half of 2011. The company had 109.2 million euros of cash and short-term investments on Dec. 31. The shares dropped 0.8 percent to 20.69 euros.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.